Article
Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
JACC. Cardiovascular interventions - 1 Jul 2010
Jeong Young-Hoon, Kim In-Suk, Park Yongwhi, Kang Min-Kyung, Koh Jin-Sin, Hwang Seok-Jae, Kwak Choong Hwan, Hwang Jin-Yong
Abstract excerpt
OBJECTIVES: This study sought to determine the impact of gene polymorphisms on platelet reactivity (PR) after clopidogrel 150 mg/day in patients treated with percutaneous coronary intervention (PCI). BACKGROUND: Although high maintenance-dose (MD) clopidogrel reduces PR, it is unknown whether gene polymorphisms are related with the risk of high post-treatment PR (HPPR) after high-MD clopidogrel. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.